BOLT Quote, Financials, Valuation and Earnings

Hepion Pharmaceuticals has a net margin of -903.44% compared to Bolt Biotherapeutics's net margin of --. Bolt Biotherapeutics's return on equity of -86.53% beat Hepion Pharmaceuticals's return on equity of --.

Bolt Biotherapeutics has a consensus price target of $2.00, signalling upside risk potential of 596.86%. On the other hand Hepion Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 3999900%. Given that Hepion Pharmaceuticals has higher upside potential than Bolt Biotherapeutics, analysts believe Hepion Pharmaceuticals is more attractive than Bolt Biotherapeutics.

Bolt Biotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Hepion Pharmaceuticals has a beta of 1.688, suggesting its more volatile than the S&P 500 by 68.792%.

Bolt Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hepion Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bolt Biotherapeutics pays -- of its earnings as a dividend. Hepion Pharmaceuticals pays out -- of its earnings as a dividend.

Bolt Biotherapeutics quarterly revenues are $1.2M, which are larger than Hepion Pharmaceuticals quarterly revenues of --. Bolt Biotherapeutics's net income of -$11M is lower than Hepion Pharmaceuticals's net income of -$6.1M. Notably, Bolt Biotherapeutics's price-to-earnings ratio is -- while Hepion Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bolt Biotherapeutics is 1.14x versus -- for Hepion Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Krystal Biotech has a net margin of -903.44% compared to Bolt Biotherapeutics's net margin of 40.52%. Bolt Biotherapeutics's return on equity of -86.53% beat Krystal Biotech's return on equity of 13.91%.

Bolt Biotherapeutics has a consensus price target of $2.00, signalling upside risk potential of 596.86%. On the other hand Krystal Biotech has an analysts' consensus of $208.00 which suggests that it could grow by 38.59%. Given that Bolt Biotherapeutics has higher upside potential than Krystal Biotech, analysts believe Bolt Biotherapeutics is more attractive than Krystal Biotech.

Bolt Biotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Krystal Biotech has a beta of 0.675, suggesting its less volatile than the S&P 500 by 32.514%.

Bolt Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bolt Biotherapeutics pays -- of its earnings as a dividend. Krystal Biotech pays out -- of its earnings as a dividend.

Bolt Biotherapeutics quarterly revenues are $1.2M, which are smaller than Krystal Biotech quarterly revenues of $88.2M. Bolt Biotherapeutics's net income of -$11M is lower than Krystal Biotech's net income of $35.7M. Notably, Bolt Biotherapeutics's price-to-earnings ratio is -- while Krystal Biotech's PE ratio is 36.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bolt Biotherapeutics is 1.14x versus 13.43x for Krystal Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Protagenic Therapeutics has a net margin of -903.44% compared to Bolt Biotherapeutics's net margin of --. Bolt Biotherapeutics's return on equity of -86.53% beat Protagenic Therapeutics's return on equity of --.

Bolt Biotherapeutics has a consensus price target of $2.00, signalling upside risk potential of 596.86%. On the other hand Protagenic Therapeutics has an analysts' consensus of -- which suggests that it could grow by 6392.75%. Given that Protagenic Therapeutics has higher upside potential than Bolt Biotherapeutics, analysts believe Protagenic Therapeutics is more attractive than Bolt Biotherapeutics.

Bolt Biotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Protagenic Therapeutics has a beta of 0.354, suggesting its less volatile than the S&P 500 by 64.562%.

Bolt Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protagenic Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bolt Biotherapeutics pays -- of its earnings as a dividend. Protagenic Therapeutics pays out -- of its earnings as a dividend.

Bolt Biotherapeutics quarterly revenues are $1.2M, which are larger than Protagenic Therapeutics quarterly revenues of --. Bolt Biotherapeutics's net income of -$11M is lower than Protagenic Therapeutics's net income of -$1.4M. Notably, Bolt Biotherapeutics's price-to-earnings ratio is -- while Protagenic Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bolt Biotherapeutics is 1.14x versus 0.13x for Protagenic Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Rigel Pharmaceuticals has a net margin of -903.44% compared to Bolt Biotherapeutics's net margin of 21.46%. Bolt Biotherapeutics's return on equity of -86.53% beat Rigel Pharmaceuticals's return on equity of --.

Bolt Biotherapeutics has a consensus price target of $2.00, signalling upside risk potential of 596.86%. On the other hand Rigel Pharmaceuticals has an analysts' consensus of $33.74 which suggests that it could grow by 75.01%. Given that Bolt Biotherapeutics has higher upside potential than Rigel Pharmaceuticals, analysts believe Bolt Biotherapeutics is more attractive than Rigel Pharmaceuticals.

Bolt Biotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Rigel Pharmaceuticals has a beta of 1.264, suggesting its more volatile than the S&P 500 by 26.398%.

Bolt Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rigel Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bolt Biotherapeutics pays -- of its earnings as a dividend. Rigel Pharmaceuticals pays out -- of its earnings as a dividend.

Bolt Biotherapeutics quarterly revenues are $1.2M, which are smaller than Rigel Pharmaceuticals quarterly revenues of $53.3M. Bolt Biotherapeutics's net income of -$11M is lower than Rigel Pharmaceuticals's net income of $11.4M. Notably, Bolt Biotherapeutics's price-to-earnings ratio is -- while Rigel Pharmaceuticals's PE ratio is 9.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bolt Biotherapeutics is 1.14x versus 1.69x for Rigel Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.